Exit
Before you view this activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. 68yo female with metastatic urothelial carcinoma (mUC)
  • Status post treatment with enfortumab vedotin and pembrolizumab
  • On pembrolizumab monotherapy for 12 months
  • FGFR3 and cisplatin eligible
  • Presents with new liver metastases
In your practice, what would you use next?

Question Title

* 4. 74yo female status post treatment with gem/ + cisplatin
  • Avelumab maintenance x12m
  • 🧬No FGFR3 alterations, HER2 IHC 0
  • Presents with new liver mets
What treatment should you use next?

Question Title

* 5. 67 year old male patient with mUC status post treatment with EV+P
  • FGFR3 alteration
  • Treated with erdafitinib in the second-line
  • Serum phosphate 8.0 mg/dL
What should you do next?

Question Title

* 6. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).

Completing the fields below does not immediately qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

*Please note that we will not forward or sell your contact information.

🔗 Proceed to activity on www.x.com (only available after program launch date)
🔗 Proceed to activity post-survey
(post-survey completion must occur on or after activity launch date and prior to activity expiration date to be valid for claiming credit)
( Privacy & Cookie Notice